This site is intended for healthcare professionals
Drug news

Ra Pharmaceuticals announces dosing of first patient in phase III pivotal study of zilucoplan for generalized myasthenia gravis.

Read time: 1 mins
Last updated:12th Oct 2019
Published:12th Oct 2019
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest